Shigehiro Yokoi
Yoshida Gun, 9101193, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study.
Journal: Medicina (Kaunas, Lithuania)
Published: February 20, 2026
A Case Report of Triple-Negative Breast Cancer with High Ki-67 Expression That Responded to Neoadjuvant Pembrolizumab Therapy
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
A Case Report of Metastatic Breast Cancer with Peritoneal Metastasis and Massive Ascites Responding to CDK4/6 Inhibitor(Palbociclib)
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: March 07, 2024
Possible spontaneous regression of hepatocellular carcinoma with unique histopathological features confirmed by surgical resection: a case report.
Journal: Surgical case reports
Published: May 20, 2021
Conversion Therapy for HER2-Positive Metastatic Breast Cancer with Intrathoracic Lymph Node Metastasis
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 17, 2020
Double primary recurrent human epidermal growth factor receptor 2-positive breast cancer and esophageal cancer that responded well to chemotherapy.
Journal: International cancer conference journal
Published: March 26, 2018
Sericin in the isolating solution improves the yield of islets isolated from the pancreas.
Journal: Cytotechnology
Published: November 27, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026